Key Takeaways
- Lexicon is squarely focused on a Phase IIb data readout for pilavapadin, or LX9211, for diabetic peripheral neuropathic pain (DPNP), coming in the first quarter.
- The trial readout is Lexicon’s sole near-term clinical catalyst and success could position the company for a rebound after a disappointing 2024.
- CEO Mike Exton talked to Scrip in an interview about a reorganization at Lexicon and why the company is optimistic about the upcoming data readout.
Lexicon Pharmaceuticals has an important data readout coming in the first quarter for a Phase IIb study testing pilavapadin, or LX9211, for diabetic peripheral neuropathic pain (DPNP)
The data readout will be Lexicon’s big chance to show investors that it can successfully reposition into a clinical-stage company focused on first-in-class products after a big setback last